Promising results from the phase II clinical trial of triplet combination of nivolumab with dabrafenib and trametinib (TRIDeNT) in patients with PD1 naïve or refractory BRAF-mutated metastatic melanoma have also been published [167]. This evidence concerns the gene BRAF and metastatic melanoma.